Kenvue (FRA:J4D) Asset Impairment Charge : €474 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Kenvue Asset Impairment Charge?

Kenvue's Asset Impairment Charge for the three months ended in Mar. 2025 was €0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was €474 Mil.

Kenvue Asset Impairment Charge Historical Data

The historical data trend for Kenvue's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kenvue Asset Impairment Charge Chart

Kenvue Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

-28.77

-7.97

11.33

551.99

Kenvue Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial										62.56	473.79	-	-	-

Kenvue Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €474 Mil.

Kenvue Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Kenvue's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Kenvue Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Kenvue Inc (FRA:J4D) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

KVUE:USA J4D:Germany

Address

199 Grandview Road, Skillman, NJ, USA, 08558

Website

https://www.kenvue.com

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Kenvue Headlines

No Headlines